Global Wilson's Disease Drugs Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Wilson's Disease Drugs Market Research Report 2024
Wilson’s disease is also known as progressive lenticular degeneration and hepatolenticular degeneration that causes copper poisoning in the body. Copper is a necessary element for cellular functions; however, excessive copper is extremely toxic and can cause permanent damage to cellular functions of body. Wilson’s disease is caused by excessive deposition of copper in the body. Generally, copper is released into bile from the diet is cleaned out by the liver, flowing out of the body from the gastrointestinal tract. Wilson’s disease occurs due to excessive deposition of copper in the brain, liver, and other tissues of the body. According to the American Association for the Study of Liver Diseases, Wilson’s disease occurs worldwide with prevalence of approximately 30 individuals affected per million.
According to Mr Accuracy reports’s new survey, global Wilson's Disease Drugs market is projected to reach US$ 307.4 million in 2034, increasing from US$ 204.1 million in 2024, with the CAGR of 5.9% during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Wilson's Disease Drugs market research.
The classification of Wilson’s disease includes Trientine, Penicillamine and others, and the proportion of Trientine in 2019 is about 47%. Penicillamine was the first drug approved for the treatment of Wilson’s disease. Penicillamine is the most successful drug used for the treatment of Wilson’s disease. Wilson’s disease is widely used in Hospital, drugs stores and other field. The most proportion of Wilson’s disease is Drugs Store, and the proportion in 2019 is 51%. North America is the largest consumption place, with a consumption market share nearly 76.93% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 10.51%. Market competition is intense. Bausch Health, Teva, Endo International, Univar Solutions, MSN Laboratories, etc. are the leaders of the industry.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Wilson's Disease Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Kadmon Holdings, Inc.
Merck & Co.
Teva Pharmaceutical Industries Limited
Tsumura & Co.
Valeant Pharmaceuticals International, Inc.
VHB Life Sciences, Inc.
Wilson Therapeutics AB (Alexion)
Segment by Type
Hepatic
Neuropsychiatric
Ophthalmic
Others
Hospitals
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Wilson's Disease Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Wilson's Disease Drugs market is projected to reach US$ 307.4 million in 2034, increasing from US$ 204.1 million in 2024, with the CAGR of 5.9% during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Wilson's Disease Drugs market research.
The classification of Wilson’s disease includes Trientine, Penicillamine and others, and the proportion of Trientine in 2019 is about 47%. Penicillamine was the first drug approved for the treatment of Wilson’s disease. Penicillamine is the most successful drug used for the treatment of Wilson’s disease. Wilson’s disease is widely used in Hospital, drugs stores and other field. The most proportion of Wilson’s disease is Drugs Store, and the proportion in 2019 is 51%. North America is the largest consumption place, with a consumption market share nearly 76.93% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 10.51%. Market competition is intense. Bausch Health, Teva, Endo International, Univar Solutions, MSN Laboratories, etc. are the leaders of the industry.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Wilson's Disease Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Kadmon Holdings, Inc.
Merck & Co.
Teva Pharmaceutical Industries Limited
Tsumura & Co.
Valeant Pharmaceuticals International, Inc.
VHB Life Sciences, Inc.
Wilson Therapeutics AB (Alexion)
Segment by Type
Hepatic
Neuropsychiatric
Ophthalmic
Others
Segment by Application
Hospitals
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Wilson's Disease Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices